PACTR201608001741317已完成未知
An exploratory, single-centre, single-dose, open-label, randomised, three-way crossover study to investigate the pharmacokinetics of three orally inhaled formulations containing fluticasone propionate and salmeterol (as xinafoate) 50/25 ¿g per actuation administered from a pressurised metered dose inhaler, in at least 24 healthy male and female subjects
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 100 Year(s)（—）
- 性别
- All
入选标准
- •1. Healthy male and female subjects, 18 years and older;
- •2. Body mass index (BMI) between 18.5 and 30 kg/m2 (both inclusive);
- •3. Body mass not less than 52 kg for males and 57 kg for females;
- •4. Medical history, vital signs, physical examination, standard 12 lead electrocardiogram (ECG) and laboratory investigations must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the Investigator considers the deviation to be irrelevant for the purpose of the study;
- •5. Non-smokers;
- •6. Females, if: Not of childbearing potential, e.g., been surgically sterilised, undergone hysterectomy, amenorrhea for ¿ 12 months and considered post menopausal; OR Of childbearing potential, following conditions to be met: Negative pregnancy test; If test positive, subject will be excluded from study. In rare circumstance that pregnancy discovered after subject receives IMP, every attempt must be made to follow her to term; Not lactating; Abstaining from sexual activity (if this is usual lifestyle of subject) or must agree to use accepted method of contraception, and agree to continue with same method throughout the study; Examples of reliable methods of contraception include non hormonal intrauterine device, barrier methods combined with additional contraceptive method; Other methods, if considered by the Investigator as reliable, will be accepted;
- •7. Subjects with normal potassium levels (according to local laboratory reference ranges);
- •8. Written consent given for participation in the study.
排除标准
- •1. Psychiatric disorder or emotional, personality or intellectual problems likely to limit ability to consent or comply with study requirements;
- •2. Excess alcohol use;
- •3. Regular exposure to substances of abuse (other than alcohol) within past year;
- •4. Use within 2 weeks before IMP administration of any medication or other remedies that may interfere with the conduct or results of the study;
- •5. Concomitant use of hormonal replacement therapy or hormonal contraceptives;
- •6. Participation in a clinical investigation within 8 weeks before IMP administration in this study;
- •7. Use of any drug with well-defined potential for adversely affecting any organ or system, within 3 months before IMP administration;
- •8. Major illness in 3 months before start of screening;
- •9. History of hypersensitivity or allergy to IMP, excipients or related medication;
- •10. History of asthma or other bronchospastic disease;
- •11. History of epilepsy, porphyria, or current cataracts or glaucoma;
- •15. History of oral candida requiring treatment in last 3 years;
- •16. History, laboratory or clinical findings indicative of disease likely to influence study outcomes;
- •17. Conditions causing hypokalemia;
- •18. Blood loss equal to or exceeding 500 mL within 8 weeks before IMP administration;
- •19. Hypotension diagnosed at screening;
- •20. Current hypertension or diagnosis at screening;
- •21. Resting tachy- or bradycardia at screening;
- •22. Positive HIV, Hepatitis B or Hepatitis C tests;
- •23. Positive urinary drugs of abuse or cotinine;
- •24. Positive pregnancy test;
- •25. Inadequate inhalation technique at screening;
- •26. FEV1 < 80% predicted value;
- •27. Immunisation with live vaccine within 4 weeks before IMP administration;
- •28. Vulnerable subjects.
研究者
相似试验
已完成
1 期
A single dose study in healthy Japanese participants to evaluate the safety and pharmacokinetics of otilimab.Rheumatoid ArthritisJPRN-jRCT2071210132Yamada Masanori12
未知
1 期
A single-center, open-label, single-dose study investigating the safety, tolerability, and pharmacokinetic properties of nalmefene 10 mg tablets in healthy Japanese male subjectsHealthy adult maleJPRN-jRCT2080223097Otsuka Pharmaceutical Co., Ltd.7
进行中（未招募）
不适用
A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prostatic hyperplasia - FE 200486 CS25Patients with Benign Prostata Hypertropia (BPH) who fulfil the following criteria: a prostate volume of more than 30 mL, maximal uroflow of 12 mL/s or lessInternational Prostate Symptom Score (IPSS) of 13 or more, a serum prostate specific antigen (PSA) value below 10 ng/mL and no evidence of prostate cancer will be included in the studyMedDRA version: 9.1Level: LLTClassification code 10004447Term: Benign prostatic hypertrophyEUCTR2007-003578-24-DEFerring Pharmaceuticals A/S
进行中（未招募）
Unknown
Bioavailability study of DOXIL/CAELYX (2 mg/mL) in patients with advanced or refractory ovarian or breast cancer.CTRI/2023/08/056252Baxter Healthcare Corporation
进行中（未招募）
1 期
A Study of Nasal Glucagon in Children with Insulin Dependent Diabetessevere hypoglycemiaEUCTR2021-006088-61-Outside-EU/EEAEli Lilly and Company